When researchers learned that a class of drugs initially used to treat type 2 diabetes could also bring weight loss, the drugs Victoza and Ozempic gained popularity as a treatment option for obesity.

Given as daily or weekly injections, these drugs called GLP-1 RAs, help people produce insulin and lower the amount of sugar in the blood.

First approved for use in type 2 diabetes patients in 2005 by the U.S. Food and Drug Administration, the medications were quickly noted to promote weight loss.

If there is one thing that millions in this world would wish for, it would be weight loss in a pill and for decades, scientists have been trying to crack the obesity code but success has eluded them at every juncture.

Of the nearly 35 million Americans with type 2 diabetes, more than one in 10 were estimated to be taking these drugs in 2019, according to the Journal of the American Medical Association.

Most people do well when they are in the program but it is not possible to be on a diet forever. At the other end of the spectrum, we have the option of bariatric surgery however, not everyone is eligible for surgical treatment of obesity.

As per the guidelines of the Obesity and Metabolic Surgery Society of India (OSSI), a person with a BMI 35 Kg/m2 without any co-morbidities or a person with a BMI 30 Kg/m2 with any two co-morbidities like diabetes

It is said that eight out of ten people need some additional intervention for significant weight loss and weight maintenance.